Common Names
Geographic Range: Central Asia, China (Inner Mongolia, Xinjiang, Gansu), Russia, Kazakhstan. G. glabra native to Mediterranean/Middle East.
Known Contraindications
1
Compounds
4
Traditions
7
Treatments
6
Conditions
O=C(O)[C@@H]1O[C@@H](OC2CC[C@@]3(C)[C@H](CC[C@]4(C)[C@@H]3C(=O)C=C3[C@@H]5C[C@@](C)(CC(=O)O)[C@H](O)C[C@H]5CC[C@@]34C)C2)[C@H](O)[C@@H](O)[C@H]1OCYP Interaction Profile
| Enzyme | Interaction |
|---|---|
| CYP1A2 | no significant interaction |
| CYP2B6 | weak substrate |
| CYP2C9 | weak substrate |
| CYP2D6 | no significant interaction |
| CYP3A4 | moderate inducer |
| CYP2C19 | no significant interaction |
| clinical_note | Moderate CYP3A4 inducer and P-gp inhibitor. Potassium-depleting effect may potentiate digoxin toxicity. Avoid with antihypertensives and diuretics. |
| transporter_note | Inhibits P-glycoprotein — may increase bioavailability of P-gp substrates (digoxin, fexofenadine) |